[New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options]

Area of Science:

• Urology
• Pharmacology
• Sexual Medicine

Background:

• Erectile dysfunction (ED) affects millions globally, necessitating effective therapeutic strategies.
• Recent decades have seen profound changes in ED pharmacotherapy due to new drug development.

Purpose of the Study:

• To review current pharmacologic and non-pharmacologic treatment options for erectile dysfunction.
• To highlight the efficacy, administration, and contraindications of various ED medications.
• To emphasize the importance of individualized treatment approaches for ED.

Main Methods:

• Review of current literature on pharmacologic treatments for erectile dysfunction.
• Categorization of drugs into initiators versus conditioners and central- or peripheral-acting agents.
• Inclusion of non-pharmacologic options such as vacuum devices and penile implants.

Main Results:

• Pharmacologic options include prostaglandin E(1) (PGE(1)), yohimbine, apomorphine, and phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil, tadalafil).
• PDE-5 inhibitors offer high efficacy (50-80%) with manageable side effects, but contraindications like nitrate use must be observed.
• Non-pharmacologic options like vacuum devices and penile implants are effective when medical treatments fail.

Conclusions:

• A wide array of treatment options exists for erectile dysfunction, ranging from oral medications to surgical interventions.
• Individualized patient assessment and tailored therapy are crucial for achieving satisfactory sexual function.
• Collaboration among medical disciplines ensures comprehensive care for patients with ED.